

**DCAT**

# TOP Industry NEWS

*BUSY WEEK? Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*



**DCAT**

**AFTER** THE SHOW *A Member Company Networking Event*

BARCELONA 2016

WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR

## **1. Teva Completes \$40.5 Billion Acquisition of Allergan's Generics Business**

Teva Pharmaceutical Industries has completed its \$40.5 billion acquisition of the generics business of Allergan. With the closing, Teva has acquired Allergan's legacy Actavis Global Generics business, including the US and international generic commercial units, third-party supplier Medis, global generic manufacturing operations, and the global generic R&D unit, as well as Allergan's international over-the-counter (OTC) commercial unit (excluding OTC eye care products) and certain established international brands. [Read More](#)

## **2. GSK, Google Partner To Form New Bioelectronics Pharma Company**

GlaxoSmithKline (GSK) has signed an agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development, and commercialization of bioelectronic medicines. Galvani Bioelectronics will be headquartered in the UK, with the parent companies contributing existing intellectual property rights and an investment of up to £540 million (\$721 million) over seven years, subject to successful completion of various discovery and development milestones. [Read More](#)

## **3. Takeda Announces R&D Restructuring**

Takeda Pharmaceutical Company Limited plans to accelerate its research & development (R&D) organization transformation by refocusing on three key therapeutic areas (oncology, gastroenterology, and central nervous system), plus vaccines, and concentrating R&D activities in Japan and the US. Takeda estimates one-time implementation costs of approximately 75 billion yen (\$742 million) and annual cost savings of approximately 18 billion yen (\$178 million) after implementation. [Read More](#)

## **4. Meda Shareholders Accept Mylan's Tender Offer**

Mylan's public offer to the shareholders of Meda Aktiebolag, a Swedish pharmaceutical company, to tender all their shares in Meda to Mylan has been accepted, amounting to 94% of the total number of outstanding shares and votes in Media as part of Mylan's \$7.2 billion acquisition of Meda. Last week, the US Federal Trade Commission cleared the acquisition subject to the divestment of certain products by Mylan. [Read More](#)

## **5. Pfizer Acquires Bamboo Therapeutics To Boost Position in Gene**

## Therapy

Pfizer has acquired Bamboo Therapeutics, a privately held biotechnology company focused on developing gene therapies. The deal provides Pfizer with a clinical and several preclinical assets that complement Pfizer's rare disease portfolio, an advanced recombinant adeno-associated virus vector design and production technology, and a Phase I/II gene therapy manufacturing facility that Bamboo acquired from the University of North Carolina. [Read More](#)

### **6. Mayne Completes \$625 Million Acquisition of Generic Products from Teva**

Mayne Pharma has completed its previously announced \$652 million acquisition of 37 approved and five filed generic pharmaceutical products from Teva Pharmaceutical Industries, following Teva's closing of its \$40.5 billion acquisition of the generics business of Allergan. Teva had to divest the products as part of requirements with the US Federal Trade Commission to secure clearance for that deal. [Read More](#)

### **7. Astellas Transfers US Manufacturing Subsidiary to CMO**

Astellas Pharma has transferred its wholly owned manufacturing subsidiary, Astellas Pharma Technologies (APT), based in Norman, Oklahoma, to Avara Pharmaceutical Services, a CMO, headquartered in Norwalk, Connecticut. APT will be renamed Avara Pharmaceutical Technologies. APT owns the plant used for the formulation and packaging of certain Astellas pharmaceutical products, which has now been transferred to Avara, along with a supply pact with Astellas. [Read More](#)

### **8. Piramal Pharma Solutions To Expand Sterile Manufacturing Capacity**

Piramal Pharma Solutions, a provider of sterile drug product development and manufacturing services, has announced plans for a \$25 million expansion of its facilities in Lexington, Kentucky, which includes adding commercial aseptic manufacturing. [Read More](#)

### **9. EMA Announces Reorganization**

The European Medicines Agency (EMA) has announced some organizational adjustments and important strategic amendments of its corporate management structure that the agency says will result in a leaner, more streamlined architecture and improved administrative support. The changes fine-tune a re-engineered organizational model to further improve efficiency and effectiveness of EMA's operations. All changes will come into effect on September 1, 2016. [Read More](#)

### **10. FDA OKs Sanofi's Diabetes Drug**

The FDA has approved Sanofi's Adlyxin (lixisenatide), a once-daily injection to improve glycemic control, along with diet and exercise, in adults with Type 2 diabetes. Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar level [Read More](#)

## **\*\*Upcoming DCAT Event\*\***

### **DCAT After the Show**

Don't miss DCAT's inaugural networking event following CPhI Worldwide in Barcelona on Wednesday, October 5th from 6:00 PM to 8:30 PM at the beautiful Casa Llotja de Mar. Located just steps away from the Gothic Quarter and Port of Barcelona, this event offers the perfect opportunity to utilize that time between the tradeshow and your late-night dinner plans to catch up with colleagues and establish valuable industry connections.

Registration for this event is now open. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

## **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)